top of page
Search

Autoimmune-Summaries: Daily Autoimmune Updates at a Glance

  • decodeMR Team
  • 3 hours ago
  • 1 min read

13/04/2026









Saphnelo® subcutaneous approved in Canada for the treatment of SLE (Ref)


Astrazeneca announced that Health Canada had granted a Notice of Compliance (NOC) for Saphnelo® (anifrolumab; type 1 IFNR) for subcutaneous self-administration via a single-use autoinjector in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) in addition to standard therapy


  • The approval by Health Canada was based on positive results from the interim analysis of the Phase III TULIP-SC trial


  • In the trial, the subcutaneous administration of anifrolumab led to a statistically significant and clinically meaningful reduction in disease activity compared with placebo in participants with active, autoantibody-positive SLE who were receiving standard therapy


  • Th new self-administration option offered the same clinical benefits as Saphnelo IV infusion




bottom of page